Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Aug;80(12):1962–1967. doi: 10.1038/sj.bjc.6690627

Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5-fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma: a phase II study

R L Hong 1, T S Sheen 2, J Y Ko 2, M M Hsu 2, C C Wang 1, L L Ting 3
PMCID: PMC2363155  PMID: 10471046

Abstract

The combination of cisplatin and 5-fluorouracil (5-FU) (PF) is the most popular regimen for treating metastatic nasopharyngeal carcinoma (NPC) but it is limited by severe stomatitis and chronic cisplatin-related toxicity. A novel approach including induction with mitomycin C, doxorubicin and cisplatin (MAP) and subsequent maintenance with weekly 5-FU and leucovorin (FL) were designed with an aim to reduce acute and chronic toxicity of PF. Thirty-two patients of NPC with measurable metastatic lesions in the liver or lung were entered into this phase II trial. Mitomycin C 8 mg m−2, doxorubicin 40 mg m−2 and cisplatin 60 mg m−2 were given on day 1 every 3 weeks as initial induction. After either four courses or remission was achieved, patients received weekly dose of 5-FU 450 mg m−2 and leucovorin 30 mg m−2 for maintenance until disease progression. With 105 courses of MAP given, 5% were accompanied by grade 3 and 0% were accompanied by grade 4 stomatitis. The dose-limiting toxicity of MAP was myelosuppression. Forty per cent of courses had grade 3 and 13% of courses had grade 4 leukopenia. No grade 3 or 4 cisplatin-related toxicity was observed. The overall response rate was 94% (95% confidence interval (CI) 84.9–100%) with a complete response rate (CR) of 6% (95% CI: 0–15.2%) and a good partial response (PR) rate of 28% (95% CI 11.7–44.6%), which was optionally defined as observance of only equivocal lesion identifiable under imaging study. Twenty-seven cases entered weekly FL maintenance phase. The median duration of maintenance with weekly FL was 38 weeks (8–91 weeks). There was no grade 3 or 4 toxicity noted during weekly FL. The median progression-free survival and overall survival were 11.6 ± 0.4 and 18.1 ± 3.6 months respectively. Six patients with a median follow-up of 19.8 months (9.6–41.0 months) were still alive and five of them had disease under control with FL. Good responders (CR and good PR) had better survival than less satisfactory responders (PR and stable disease) (P = 0.05). From Cox’s multivariate regression analysis, the only significant prognostic factor for survival was good response to MAP (P = 0.042). Liver metastasis was the only significant variable in the best subset regression model that predicted good response to MAP (CR and good PR) (P = 0.027). MAP was an effective combination for metastatic NPC with minimal stomatitis and cisplatin-related toxicity but had significant myelosuppression. Weekly FL was a maintenance therapy with minimal side-effects. The response rate and overall survival of MAP-FL were better than series previously reported even when a subset of patients with poor prognosis was selected. MAP-FL's role as neoadjuvant or adjuvant therapy is worthy of further study. © 1999 Cancer Research Campaign

Keywords: nasopharyngeal carcinoma, metastasis, chemotherapy, mitomycin, cisplatin

Full Text

The Full Text of this article is available as a PDF (72.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boussen H., Cvitkovic E., Wendling J. L., Azli N., Bachouchi M., Mahjoubi R., Kalifa C., Wibault P., Schwaab G., Armand J. P. Chemotherapy of metastatic and/or recurrent undifferentiated nasopharyngeal carcinoma with cisplatin, bleomycin, and fluorouracil. J Clin Oncol. 1991 Sep;9(9):1675–1681. doi: 10.1200/JCO.1991.9.9.1675. [DOI] [PubMed] [Google Scholar]
  2. Chi K. H., Chan W. K., Cooper D. L., Yen S. H., Lin C. Z., Chen K. Y. A phase II study of outpatient chemotherapy with cisplatin, 5-fluorouracil, and leucovorin in nasopharyngeal carcinoma. Cancer. 1994 Jan 15;73(2):247–252. doi: 10.1002/1097-0142(19940115)73:2<247::aid-cncr2820730203>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  3. Chi K. H., Chan W. K., Shu C. H., Law C. K., Chen S. Y., Yen S. H., Chen K. Y. Elimination of dose limiting toxicities of cisplatin, 5-fluorouracil, and leucovorin using a weekly 24-hour infusion schedule for the treatment of patients with nasopharyngeal carcinoma. Cancer. 1995 Dec 1;76(11):2186–2192. doi: 10.1002/1097-0142(19951201)76:11<2186::aid-cncr2820761103>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  4. Choo R., Tannock I. Chemotherapy for recurrent or metastatic carcinoma of the nasopharynx. A review of the Princess Margaret Hospital experience. Cancer. 1991 Nov 15;68(10):2120–2124. doi: 10.1002/1097-0142(19911115)68:10<2120::aid-cncr2820681005>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  5. Cvitkovic E., Bachouchi M., Armand J. P. Nasopharyngeal carcinoma. Biology, natural history, and therapeutic implications. Hematol Oncol Clin North Am. 1991 Aug;5(4):821–838. [PubMed] [Google Scholar]
  6. Day R. S. Treatment sequencing, asymmetry, and uncertainty: protocol strategies for combination chemotherapy. Cancer Res. 1986 Aug;46(8):3876–3885. [PubMed] [Google Scholar]
  7. Decker D. A., Drelichman A., Al-Sarraf M., Crissman J., Reed M. L. Chemotherapy for nasopharyngeal carcinoma. A ten-year experience. Cancer. 1983 Aug 15;52(4):602–605. doi: 10.1002/1097-0142(19830815)52:4<602::aid-cncr2820520404>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  8. Drewinko B., Green C., Loo T. L. Combination chemotherapy in vitro with cis-dichlorodiammineplatinum(II). Cancer Treat Rep. 1976 Nov;60(11):1619–1625. [PubMed] [Google Scholar]
  9. Dreyfuss A. I., Clark J. R., Wright J. E., Norris C. M., Jr, Busse P. M., Lucarini J. W., Fallon B. G., Casey D., Andersen J. W., Klein R. Continuous infusion high-dose leucovorin with 5-fluorouracil and cisplatin for untreated stage IV carcinoma of the head and neck. Ann Intern Med. 1990 Feb 1;112(3):167–172. doi: 10.7326/0003-4819-112-3-167. [DOI] [PubMed] [Google Scholar]
  10. Durand R. E. Synergism of cisplatin and mitomycin C in sensitive and resistant cell subpopulations of a tumor model. Int J Cancer. 1989 Nov 15;44(5):911–917. doi: 10.1002/ijc.2910440528. [DOI] [PubMed] [Google Scholar]
  11. Fountzilas G., Skarlos D., Athanassiades A., Kalogera-Fountzila A., Samantas E., Bacoyiannis C., Nicolaou A., Dombros N., Briasoulis E., Dinopoulou M. Paclitaxel by three-hour infusion and carboplatin in advanced carcinoma of nasopharynx and other sites of the head and neck. A phase II study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol. 1997 May;8(5):451–455. doi: 10.1023/a:1008279503428. [DOI] [PubMed] [Google Scholar]
  12. Gebbia V., Zerillo G., Restivo G., Speciale R., Cupido G., Lo Bue P., Ingria F., Gallina S., Spatafora G., Testa A. Chemotherapeutic treatment of recurrent and/or metastatic nasopharyngeal carcinoma: a retrospective analysis of 40 cases. Br J Cancer. 1993 Jul;68(1):191–194. doi: 10.1038/bjc.1993.312. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Grem J. L., Hoth D. F., Hamilton J. M., King S. A., Leyland-Jones B. Overview of current status and future direction of clinical trials with 5-fluorouracil in combination with folinic acid. Cancer Treat Rep. 1987 Dec;71(12):1249–1264. [PubMed] [Google Scholar]
  14. Hsu M. M., Tu S. M. Nasopharyngeal carcinoma in Taiwan. Clinical manifestations and results of therapy. Cancer. 1983 Jul 15;52(2):362–368. doi: 10.1002/1097-0142(19830715)52:2<362::aid-cncr2820520230>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  15. Huang S. C., Lui L. T., Lynn T. C. Nasopharyngeal cancer: study III. A review of 1206 patients treated with combined modalities. Int J Radiat Oncol Biol Phys. 1985 Oct;11(10):1789–1793. doi: 10.1016/0360-3016(85)90033-1. [DOI] [PubMed] [Google Scholar]
  16. Kohno N., Inuyama Y., Sakurai S., Ohnuma T. BOMM regimen for the treatment of advanced head and neck carcinoma. Cancer Invest. 1991;9(5):485–489. doi: 10.3109/07357909109018946. [DOI] [PubMed] [Google Scholar]
  17. Lee A. W., Poon Y. F., Foo W., Law S. C., Cheung F. K., Chan D. K., Tung S. Y., Thaw M., Ho J. H. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and patterns of failure. Int J Radiat Oncol Biol Phys. 1992;23(2):261–270. doi: 10.1016/0360-3016(92)90740-9. [DOI] [PubMed] [Google Scholar]
  18. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966 Mar;50(3):163–170. [PubMed] [Google Scholar]
  19. Rockwell S., Kennedy K. A., Sartorelli A. C. Mitomycin-C as a prototype bioreductive alkylating agent: in vitro studies of metabolism and cytotoxicity. Int J Radiat Oncol Biol Phys. 1982 Mar-Apr;8(3-4):753–755. doi: 10.1016/0360-3016(82)90728-3. [DOI] [PubMed] [Google Scholar]
  20. Su W. C., Chen T. Y., Kao R. H., Tsao C. J. Chemotherapy with cisplatin and continuous infusion of 5-fluorouracil and bleomycin for recurrent and metastatic nasopharyngeal carcinoma in Taiwan. Oncology. 1993 Jul-Aug;50(4):205–208. doi: 10.1159/000227179. [DOI] [PubMed] [Google Scholar]
  21. Teicher B. A., Gunner L. J., Roach J. A. Chemopotentiation of mitomycin C cytotoxicity in vitro by platinum complexes. Br J Cancer. 1985 Dec;52(6):833–839. doi: 10.1038/bjc.1985.266. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Teo P., Tsao S. Y., Shiu W., Leung W. T., Tsang V., Yu P., Lui C. A clinical study of 407 cases of nasopharyngeal carcinoma in Hong Kong. Int J Radiat Oncol Biol Phys. 1989 Sep;17(3):515–530. doi: 10.1016/0360-3016(89)90102-8. [DOI] [PubMed] [Google Scholar]
  23. Vokes E. E., Schilsky R. L., Weichselbaum R. R., Kozloff M. F., Panje W. R. Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for locally advanced head and neck cancer: a clinical and pharmacologic analysis. J Clin Oncol. 1990 Feb;8(2):241–247. doi: 10.1200/JCO.1990.8.2.241. [DOI] [PubMed] [Google Scholar]
  24. Yeo W., Leung T. W., Leung S. F., Teo P. M., Chan A. T., Lee W. Y., Johnson P. J. Phase II study of the combination of carboplatin and 5-fluorouracil in metastatic nasopharyngeal carcinoma. Cancer Chemother Pharmacol. 1996;38(5):466–470. doi: 10.1007/s002800050512. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES